A pharmacokinetic and pharmacodynamic evaluation of colchicine sustained-release pellets for preventing gout

Gout is a common metabolic disease caused by the chronic deposition of monosodium urate (MSU) crystals in joints and tissues. Low-dose of colchicine (COL) has become the first-line drug for clinical prevention of acute gout attacks. However, their high cytotoxicity leads to a narrow therapeutic inde...

Full description

Saved in:
Bibliographic Details
Published inJournal of drug delivery science and technology Vol. 67; p. 103051
Main Authors Lv, Bai, Yang, Guobao, Wei, Yejuan, Lei, Yaran, Ding, Yaning, Gong, Wei, Wang, Yuli, Gao, Chunsheng, Han, Cuiyan
Format Journal Article
LanguageEnglish
Published Elsevier B.V 01.01.2022
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Gout is a common metabolic disease caused by the chronic deposition of monosodium urate (MSU) crystals in joints and tissues. Low-dose of colchicine (COL) has become the first-line drug for clinical prevention of acute gout attacks. However, their high cytotoxicity leads to a narrow therapeutic index and frequent toxic reactions. This study developed colchicine sustained-release pellets (COL-SRPs) using fluidized-bed technology to overcome the shortcomings of fluctuation in blood concentration and other side effects of commercial rapid release COL preparations. The COL-SRPs showed a smooth surface and spherical shape under a scanning electron microscope (SEM). The in vitro release curves of the COL-SRPs under different pH dissolution medium were not significantly different (similarity factors 2 ˃ 50). The release of COL from pellets may be a diffuse action. Pharmacokinetic studies demonstrated that the mean residence time (MRT) and tmax of the COL-SRPs group were significantly higher than those in the commercial colchicine tablets (COL-Ts) group. Pharmacodynamic studies comprehensively evaluated serum inflammatory factor indicators (IL-1β and TNF-α), liver and kidney function indexes (ALT, AST and CRE), as well as ankle joint histopathology, further suggesting that the COL-SRPs exhibited a more optimal preventive potential against acute gout attack. The COL-SRPs prepared in this study provide a powerful alternative to commercial COL-Ts by overcoming their shortcomings and having great industrial production potential. [Display omitted]
ISSN:1773-2247
DOI:10.1016/j.jddst.2021.103051